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In 2001, the U.S. Environmental Protection
Agency (EPA) adopted a revised reference
dose (RfD) for methyl mercury (MeHg) of
0.1 µg/kg/day (U.S. EPA 2001a, 2001b; Rice
et al. 2003), relying heavily on the assessment
conducted by the National Research Council
(NRC 2000). The RfD is based on neuro-
logic developmental effects measured in chil-
dren associated with exposure in utero to
MeHg from the maternal diet. The NRC and
U.S. EPA assessments employed a benchmark
dose approach to derive the lower 95% conﬁ-
dence interval on the fetal cord blood mer-
cury concentration, doubling the proportion
of children in the lowest 5% of performance
on tests of neurologic performance. The
NRC identified a cord blood concentration
of 58 µg/L (ppb) total Hg based on analysis
of the individual test judged to give the most
sensitive and robust response, whereas the
U.S. EPA identified a range of cord blood
concentrations of 46–79 µg/L based on con-
sideration of several tests. These values are in
fact concentrations, whereas the RfD is a
dose—in this case, the maternal intake dose.
The reconstruction of the maternal MeHg
intake dose that resulted in the observed cord
blood Hg concentration is a critical step in
the RfD derivation. The dose reconstruction
requires a pharmacokinetic model linking
dose and blood concentration. Two different
types of pharmacokinetic models have been
used for this purpose—a physiologically
based pharmacokinetic (PBPK) model
(Clewell et al. 1999) and the one-compart-
ment model (Stern 1997; Swartout and Rice
2000). In both types of models, the relation-
ship between cord blood concentration and
dose depends on several physiologic and meta-
bolic parameters. The values of these parame-
ters vary among individuals. The population
variability in the value of these parameters
results in variability in the output of these
models. Thus, there is no unique relationship
between a given cord blood Hg concentration
and a single maternal intake dose. Rather, this
relationship is described by a probability dis-
tribution. For the RfD to be appropriately
protective and inclusive of the variability in
the population, the estimate of intake dose
must itself be a distribution that describes this
variability. This requires that the inputs to
these pharmacokinetic models be in the form
of probability distributions. The calculation of
the outputs of these models using probability
distributions has been accomplished through
the use of Monte Carlo simulation. Both the
PBPK and pharmacokinetic models for
MeHg have been analyzed in this manner and
have yielded estimates of variability in mater-
nal dose reconstruction that are quite compa-
rable. These include two separate analyses of
the one-compartment model (Stern 1997;
Swartout and Rice 2000) and one analysis of
the PBPK model (Clewell et al. 1999; Stern
et al. 2002).
Despite the close agreement regarding vari-
ability among these analyses, signiﬁcant uncer-
tainty remains regarding the appropriate central
tendency estimates (e.g., means, medians) for
the model parameters and, consequently, for
the output of the model. This uncertainty
results from the differing assumptions and dif-
ferent data employed among these three analy-
ses (NRC 2000). In part, these differences
result from uncertainty as to whether these
parameters need to reﬂect conditions during
pregnancy and from lack of speciﬁcity as to the
period of pregnancy. Recognizing this source of
uncertainty, the NRC (2000) assessment rec-
ommended separating the central tendency and
variability aspects of the dose reconstruction.
This approach was adopted by the U.S. EPA
(2001b). In this approach, nondistributed
(i.e., single value) central tendency estimates
were selected for each parameter of the one-
compartment model. The resulting output of
the model represented a central tendency esti-
mate of the maternal intake dose. This value
was divided by an uncertainty factor derived
from the analysis of variability generated from
the probabilistic analysis of the distributions
of the parameters of the one-compartment
model. The value of the uncertainty factor was
normalized to the central tendency estimate
based on the ratio of the 50th percentile to the
1st percentile (i.e., lower 99th percentile) of the
distribution of the dose derived from variability
analysis. The resulting value is an estimate of
the dose that accounts for 99% of the interindi-
vidual variability in the dose reconstruction
(NRC 2000; Stern et al. 2002). Although this
approach makes the uncertainty in the selection
of the central tendency estimates explicit, it
does not resolve that uncertainty.
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In 2001, the U.S. Environmental Protection Agency (EPA) adopted a revised reference dose (RfD)
for methyl mercury (MeHg) of 0.1 µg/kg/day. The RfD is based on neurologic developmental
effects measured in children associated with exposure in utero to MeHg from the maternal diet.
The RfD derivation proceeded from a point of departure based on measured concentration of
mercury in fetal cord blood (micrograms per liter). The RfD, however, is a maternal dose (micro-
grams per kilogram per day). Reconstruction of the maternal dose corresponding to this cord
blood concentration, including the variability around this estimate, is a critical step in the RfD
derivation. The dose reconstruction employed by the U.S. EPA using the one-compartment phar-
macokinetic model contains two areas of signiﬁcant uncertainty: It does not directly account for
the inﬂuence of the ratio of cord blood:maternal blood Hg concentration, and it does not resolve
uncertainty regarding the most appropriate central tendency estimates for pregnancy and third-
trimester–speciﬁc model parameters. A probabilistic reassessment of this dose reconstruction was
undertaken to address these areas of uncertainty and generally to reconsider the specification of
model input parameters. On the basis of a thorough review of the literature and recalculation of
the one-compartment model including sensitivity analyses, I estimated that the 95th and 99th
percentiles (i.e., the lower 5th and 1st percentiles) of the maternal intake dose corresponding to a
fetal cord blood Hg concentration of 58 µg/L are 0.3 and 0.2 µg/kg/day, respectively. For the 99th
percentile, this is half the value previously estimated by the U.S. EPA. Key words: cord blood,
maternal, mercury, methyl mercury, Monte Carlo, one-compartment, pharmacokinetic, probabilis-
tic, reference dose, RfD. Environ Health Perspect 113:155–163 (2005). doi:10.1289/ehp.7417
available via http://dx.doi.org/ [Online 4 November 2004]Another signiﬁcant source of uncertainty
in the dose reconstruction was the failure to
adequately incorporate the cord blood:mater-
nal blood Hg ratio. The one-compartment
model specifically estimates the relationship
between maternal MeHg intake and maternal
blood Hg concentration. To extend this rela-
tionship to fetal cord blood Hg concentration,
it is necessary to estimate the maternal blood
concentration corresponding to a measured
cord blood concentration. This is done by
applying an empirically derived ratio. In the
NRC (2000) assessment, evaluation of a lim-
ited set of data led to the suggestion that this
ratio was close to 1.0. On the basis of that con-
clusion, the benchmark cord blood Hg con-
centration was assumed to adequately describe
the corresponding maternal blood Hg concen-
tration. A preliminary analysis of the literature
by the U.S. EPA (2001) suggested that the cor-
rect value for this ratio was likely to be > 1.0.
The U.S. EPA RfD derivation thus included
the uncertainty in the cord blood:maternal
blood Hg ratio as a factor in its overall uncer-
tainty factor adjustment. Nonetheless, the U.S.
EPA did not identify a central tendency esti-
mate for the cord:maternal ratio and did not
account for the variability around that esti-
mate. Thus, the appropriate contribution of
this ratio to the overall RfD remains an unre-
solved source of uncertainty.
In an attempt to resolve both of these
sources of uncertainty and to examine the
extent to which a more complete analysis
might alter the value currently employed in
the RfD derivation, I have undertaken a
reanalysis of the dose reconstruction. I have
revisited the scientific literature and have
reevaluated both central tendency estimates
and overall distributions for each of the input
parameters in the one-compartment model
with a specific emphasis on pregnancy and,
more specifically, on third-trimester–specific
values. I have also incorporated the results of
a recent analysis of the distribution of the
cord blood:maternal blood Hg ratio (Stern
and Smith 2003) into the overall analysis of
the maternal dose reconstruction.
The One-Compartment Model
For consistency with the existing U.S. EPA
RfD approach for MeHg, in this analysis I
focus on the one-compartment model rather
than the PBPK model for dose reconstruc-
tion. The one-compartment model is used
in contrast to the PBPK model because it
employs a relatively small set of parameters
whose distributions within the population are
generally well characterized. This facilitates a
more accurate and transparent assessment of
variability in the dose estimate. The one-com-
partment model predicts the relationship
between MeHg intake dose and MeHg blood
concentration under steady-state conditions
in a closed system—in this case, the maternal
system. The model is expanded to address the
relationship between maternal intake dose
and fetal cord blood by applying an empiri-
cally derived ratio to estimate the maternal
blood concentration corresponding to the
measured cord blood concentration.
The one-compartment model [NRC
2000; World Health Organization (WHO)
1990] as modified to include the cord
blood:maternal blood Hg ratio, can be
expressed as
where D is the maternal intake dose of MeHg
(micrograms per kilogram per day), C is the
measured Hg concentration in cord blood (for
this analysis, the cord blood concentration is
assumed to be the BMD (benchmark dose)
value of 58 µg/L identiﬁed by the NRC (2000),
R is the ratio of cord blood Hg concentration/
maternal blood Hg concentration (unitless), b is
the rate constant for elimination of MeHg from
the blood (per day), V is the maternal blood
volume (liters), W is the maternal body weight
(kilograms), A is the fraction of the ingested
dose that is absorbed (unitless), and F is the
fraction of the absorbed dose that is present in
the blood at steady state (unitless).
Materials and Methods
I searched the scientiﬁc and medical literature
for data relating to the parameters of the one-
compartment model. Priority was given to
data for pregnant women, particularly data
specific to the third trimester of pregnancy.
To generate both central tendency estimates
and descriptions of the distributions of the
parameters, data were selected only if they
were available as subject-speciﬁc values, sum-
mary percentiles, or graphic representations
from which distributional data could be
deduced (e.g., histograms). When two differ-
ent appropriate data sets were available for a
model parameter, the determination of whether
to combine the data sets was based on a test
(t-test and/or the nonparametric Mann-
Whitney test as appropriate) of the hypothesis
that the two data sets arose from the same
underlying distribution. Data were tested for
ﬁt to parametric distributions (generally nor-
mal or log-normal) using curve-fitting soft-
ware (BestFit for Windows, version 2.0d;
Palisade Corp., Newﬁeld, NY). In the absence
of reasonable ﬁts to parametric distributions,
distributions were described by empirical dis-
tributions (e.g., cumulative probability distri-
butions). Probabilistic (Monte Carlo) analysis
of the one-compartment model was carried
out using @Risk for Windows (version 3.5.2;
Palisade Corp.). Latin hypercube sampling
was employed to provide adequate representa-
tion of the tails of distributions. Sampling was
accomplished with 5,000 iterations because
this gave good interiteration stability in the
moments of the output distribution. Results of
the model simulations are based on the average
of ﬁve separate simulations of 5,000 iterations
each. Sensitivity analyses of central tendency
estimates and variability results were carried
out as indicated in the text. Unless otherwise
indicated, all statistical analyses were carried





Table 1 summarizes the probability distribu-
tions derived for each of the parameters in the
one-compartment model. The detailed ratio-
nale for each parameter follows. In each case,
an estimate of the true uncertainty (i.e., lack
of knowledge) in the derivation of each para-
meter is provided. Consistent with the lack of
knowledge, this estimate is semiquantitative
using a relative scale of high, medium, and
low uncertainty, based on professional judg-
ment. This estimate is then employed in the
subsequent sensitivity analysis.
C—the measured concentration of Hg in
fetal cord blood. This is an empirically derived
constant. It is a biomarker of fetal MeHg expo-
sure derived from the benchmark dose analysis
relating neurodevelopmental performance to
the measured concentration of total Hg in cord
blood (NRC 2000). Although the benchmark
dose analysis is subject to uncertainty, this
value, once derived, is carried forward as the
point of departure in the pharmacokinetic
analysis. The uncertainty in this value is dealt
with elsewhere in the overall risk assessment.
The NRC (2000) identiﬁed a value of 58 µg/L
based on its selection of the most appropriate
test of developmental performance from the
Faroe Islands study. The U.S. EPA (2001a,
2001b) identiﬁed a range of values bracketing
the NRC selection from several tests in that
study. To simplify this analysis, the single value
of 58 µg/L is used. Because this value is a con-
stant, the variability in the dose estimate is
unaffected by the speciﬁc value selected, and
the central tendency estimate of the dose scales
linearly with the selected value. This value
reﬂects measurement of the concentration of
total Hg. As discussed below, and in detail by
Stern and Smith (2003), the correct value for
the purposes of dose reconstruction is the con-
centration of MeHg + MeHg-derived inor-
ganic Hg. This value is closely estimated by the
concentration of total Hg in cord blood.
R—the cord blood:maternal blood Hg
ratio. The derivation of this value is discussed
in detail by Stern and Smith (2003). Brieﬂy,
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mean and standard deviation of the ratio from
each study were calculated from the raw data,
or estimated by probabilistic simulation, and
showed a generally close agreement across
studies for both parameters. Each study was
described as the corresponding log-normal dis-
tribution, and the distributions from the indi-
vidual studies were sampled in a meta-analysis
to generate a summary distribution. The rec-
ommended summary distribution, mean ± SD
= 1.7 ± 0.93, is used in this analysis. This ratio
has historically been expressed as cord blood
Hg/maternal blood Hg. However, the one-
compartment model requires the reciprocal
form. To avoid confusion, the historical form
of the ratio is retained, and its reciprocal (1/R)
is calculated in the model.
Based on the analysis by Stern and Smith
(2003), an estimate of low true uncertainty is
applied to this parameter.
b—the elimination rate constant for MeHg
in maternal blood. As noted above for C, total
Hg rather than MeHg was measured in cord
blood. Smith et al. (1994) and Smith and Farris
(1996) point out that if the half-life in the
blood of a dose of MeHg is measured as MeHg
per se, it will be shorter than if it is measured as
total Hg. This occurs because, even though the
inorganic metabolite is not rapidly cleared from
the blood, it is no longer measured as MeHg.
The authors therefore suggest expressing the
elimination rate of MeHg from the blood based
on MeHg-specific measurements. This is
appropriate if the rate of MeHg elimination is
employed to directly estimate the period of
time during which MeHg is present in the
blood to exert a toxic effect (i.e., area-under-
the-curve considerations). In this analysis, how-
ever, the elimination rate of MeHg is employed
to calculate the steady-state balance between the
ingestion of MeHg and its elimination. For this
purpose, the inherent toxicity of MeHg does
not enter into consideration. Thus, the appro-
priate metric is the rate of elimination of all the
Hg that entered the blood as ingested MeHg.
In maternal blood, this is closely estimated by
the concentration of total Hg (NRC 2000;
Stern and Smith 2003).
Three studies report half-lives/elimination
rates measured directly in blood from nonpreg-
nant females as well as males, Sherlock et al.
(1984), Miettinen et al. (1971), and Kershaw
et al. (1980). In the study by Miettinen et al.
(1971), ﬁve men and one woman ate a single
ﬁsh meal containing added 203Hg. The total
mass of Hg in the ﬁsh meal, including endoge-
nous Hg, was 22 µg. Neither the dose nor the
body weight of the subjects is presented.
However, if a body weight of 70 kg is assumed,
the dose can be estimated at 0.3 µg/kg. The
mean half-life was 49.87 days. Kershaw et al.
(1980) administered an intravenous dose of
Article | Estimation of maternal MeHg intake dose
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Table 1. Summary of distributions selected for parameters of the one-compartment model.
Distributions
Parameter Source Data Probability
C (concentration of Hg in cord blood) NRC 2000 58 µg/L
R (ratio of Hg concentration in cord blood to maternal blood Stern and Smith 2003 Log-normal
Mean ± SD = 1.7 ± 0.9
b [rate constant for elimination of MeHg from blood; note that this parameter is Cox et al. 1989 Empirical














V (maternal blood volume) Thomson et al. 1938, Empirical (correlated with W)











Correlated with W – r = 049
A (fraction of dose absorbed) Miettinen et al. 1971 Empirical
(modiﬁed to account A Cumulative probability







F (fraction of absorbed dose that is present in the blood at steady state) Sherlock et al. 1984, Normal
Kershaw et al. 1980 Mean ± SD = 0.052 ± 0.0095
W (maternal body weight) CDC 2004b Log-normal
Mean ± SD = 80.9 ± 16.3 kg
Correlation with V – r = 0.49MeHg ranging from 18.1 to 21.8 µg/kg/day to
four men. The mean half-life was 52.98 days.
Al-Shahristani and Shihab (1974) measured
the decrease in Hg concentration along hair
strands of 48 subjects of both sexes and ages
from 6 months to 66 years in Iraq who were
deﬁned as “patients” as a result of the MeHg
poisoning epidemic 8–12 months previously.
The mean half-life was estimated to be 72 days
with a wide range (36–189 days). The maxi-
mum hair concentrations are not provided,
and the corresponding intake doses cannot be
estimated from the available data. However,
given that the subjects were still recognized as
patients up to a year after the exposure, it is
likely that their exposures were quite high.
Because of the likelihood that the exposures
resulted in frank toxicity, and given the inabil-
ity to address the extent to which these elevated
exposures may have affected the half-life (see
below), the data from Al-Shahristani and
Shihab (1974) were not further considered.
Cox et al. (1989) presented data from the
Iraqi poisoning episode for 55 women (of the
initial cohort of 83) who were exposed to
MeHg-treated grain while pregnant and whose
exposure was sufﬁciently large to allow x-ray
fluorescence analysis of Hg in single hair
strands. The decrease in Hg concentration was
followed in their hair after they eliminated the
MeHg-treated grain from their diets. Data on
individual elimination rate as a function of
exposure are not provided, but it is reported
that hair concentration ranged from 10 to
670 ppm. This range would correspond to a
steady-state daily intake of approximately
1.2–79.6 µg/kg/day assuming a 62-kg woman
(NRC 2000). The population mean dose is not
given. Data were presented for 122 hair samples
from the 55 subjects. For generating summary
and distributional statistics, it was assumed that
each subject contributed equally to the total
number of analyzed hair strands. Data were
presented by Cox et al. (1989) as a histogram
with the half-life binned in 5-day intervals.
The frequency for the midpoint value for each
half-life bin was read off the graph. The mean
half-life for the 122 samples was 47.17 days.
Although these data do not speciﬁcally repre-
sent third-trimester conditions, they are the
only elimination rate data reported for a preg-
nant population and therefore appear to be the
most applicable to the present analysis.
However, the elevated level of exposure in this
population raises concerns that the elimination
rate may vary as a function of dose. Sherlock
et al. (1984) present data on half-life and dose
for 20 subjects given an experimental dose of
MeHg. The subjects ingested MeHg in pre-
pared fish meals two to four times per week
over a 96-day period. The mean half-life was
50.20 days. The doses varied within a relatively
small range from 0.5 to 3.6 µg/kg/day (mean =
1.6 µg/kg/day). The mean dose in the Sherlock
et al. study is encompassed by the estimated
dose range among the subjects in the Cox et al.
(1989) study. It is clear, however, from the Cox
et al. report that a significant fraction of the
study population had exposures in the upper
end of the range. In the Sherlock et al. (1984)
data set, the half-life is signiﬁcantly correlated
with the dose (rSpearman = 0.52). Based on linear
regression, the half-life increased by 3.21 days
for each microgram per kilogram per day
increase in dose (p = 0.04). The nominal half-
life at zero dose (i.e., the y-intercept) is 45 days.
As shown in Table 2, with the exception
of the Cox et al. (1989) data, the mean half-
lives of the studies for which the dose is
known or can be derived increase with increas-
ing MeHg dose. This is consistent with the
relationship observed in the Sherlock et al.
(1984) data. Thus, although the upper range
of exposures in Cox et al. (1989) exceeds the
doses in the other studies by a factor of at least
four, that study yields the smallest half-life,
with a mean value close to that predicted at
zero dose from the Sherlock et al. (1984) data.
Note, however, that the Cox et al. (1989) esti-
mate is specific to the period of pregnancy.
During pregnancy, MeHg crosses the placenta
and is retained in the fetal compartment.
Given a mean cord blood:maternal blood ratio
of 1.7 (Stern and Smith 2003), the transfer of
MeHg to the fetus is, in essence, an additional
route of maternal elimination and would be
expected to result in a shorter half-life in preg-
nant women than in nonpregnant adults.
Nonetheless, maternal elimination of MeHg
across the placenta does not preclude a con-
centration dependence for other routes of
maternal elimination. There does not appear
to be any reliable way to account for the rela-
tive influence of each of these competing
processes and thus to quantitatively adjust the
half-life estimate from Cox et al. (1989) to
account for concentration dependence. The
Cox et al. data are therefore selected as the
most appropriate estimate of half-life (and the
elimination rate constant) during pregnancy
with the caveat that the true value of the cen-
tral tendency for lower doses may be smaller
than the reported value. It should, however, be
noted that, given the relatively wide range of
exposures represented in this data set, the esti-
mate of variability may be less uncertain than
the central tendency estimate.
As shown in Figure 1, these data are not
closely fit by parametric distributions, and
there is a suggestion of a bimodal distribution.
They are therefore described by an empirical
distribution whose minimum and maximum
are calculated as mean ± 3 SD.
The pregnancy-speciﬁc nature of the Cox
et al. (1989) half-life data, and its lower mean
value, consistent with fetal transport, implies
that the data are relatively speciﬁc. The method-
ology of tracking elimination through hair seg-
ments is also relatively accurate. On the other
hand, the possibility that the central tendency
estimate is biased high due to the high dose to
this population produces some uncertainty in
this estimate. An overall estimate of medium
true uncertainty is therefore assigned to this
parameter.
V—the maternal blood volume. Given the
half-life of MeHg in maternal blood, the con-
centration in cord blood reﬂects maternal expo-
sures during the last half of the third trimester
(NRC 2000). Therefore, the most appropriate
measure of maternal blood volume (V) is the
blood volume during the third trimester of
pregnancy. Blood volume increases during
pregnancy starting at the sixth to eighth week
and reaching a maximum at 32–34 weeks with
a volume about 40% larger than the nonpreg-
nant state (Fredriksen 2001).
Limited data on third-trimester blood vol-
umes in the United States from which esti-
mates of population variability can be derived
are available from early work. Only data gen-
erated < 30 days before delivery were con-
sidered for the purposes of this analysis.
Thomson et al. (1938) present data on third-
trimester blood volume for 11 women (mean
± SD = 5.42 ± 0.92 L). Caton et al. (1951)
present third-trimester data for 10 women
Article | Stern
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Table 2. MeHg half-life and elimination rate as a function of intake dose.
Mean dose Mean elimination
Study No. µg/kg/day (range) Mean T1/2 (days) rate constant (b)
Cox et al. 1989 55 (1.2–79.6)a 47.2 0.0147
Miettinen et al. 1971 6 0.3b 49.9 0.0142
Sherlock et al. 1984 20 1.6 (0.5–3.6) 50.2 0.0140
Kershaw et al. 1980 4 20.0 (18.1–20.9) 53.0 0.0133
aEstimated from reported hair Hg concentrations based on the one-compartment pharmacokinetic model, and assuming a
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Figure 1. Comparison of Cox et al. (1989) half-life
data to maximum likelihood normal and log-normal
distributions. (mean ± SD = 5.74 ± 0.97 L). Analysis of
these data sets indicates that they are consis-
tent with the hypothesis that both arise from
the same underlying distribution (pt-test =
0.44). They are therefore combined into a
single data set (n = 21, mean ± SD = 5.57 ±
0.93 L). Although these data are relatively
old, Hytten (1985), in summarizing the more
recent state of knowledge of blood volume at
40 weeks of pregnancy, reported a value of
5.50 L. The earlier studies thus appear to com-
pare well with more recent data. Thomson
et al. (1938) also report the measured body
weight corresponding to the blood volumes.
Third-trimester blood volume and body weight
are moderately correlated (rSpearman = 0.49),
but the correlation is marginally significant
(p = 0.13). Body weight and blood volume are
known to be correlated in general (Fredriksen
2001; Hytten 1985). Therefore, the lack of
signiﬁcance for this correlation in the Thomson
et al. (1938) data likely reﬂects the small sample
size rather than the absence of a meaningful
correlation.
As seen in Figure 2, the combined data set
is not well described by parametric distribu-
tions, and there is a suggestion of polymodal-
ity. These data are therefore described as an
empirical distribution, with minimum and
maximum values chosen as mean – 2 SD and
mean + 2.5 SD, respectively. The nonsym-
metrical bounds are chosen to accommodate
the right-skewness of the data. In the proba-
bilistic analysis, samples of V and maternal
body weight at delivery (W) are mutually con-
strained by the correlation coefﬁcient derived
from the Thomson et al. (1938) data.
These data are highly speciﬁc to the target
population. Although the combined data set
for this parameter is relatively small, the overall
variance is also small (coefﬁcient of variation =
0.17), as would be expected given the physio-
logic constraints on blood volume. Thus, it is
not likely that a larger sample would signifi-
cantly change the parameters of the resulting
distribution. Despite the age of the data, they
appear consistent with more contemporary
estimates. This parameter is therefore judged to
have a low true uncertainty.
A—the fraction of the dose that is absorbed.
This parameter is a measure of the fraction of
the mass of ingested MeHg that is absorbed
into the body as a whole. As such, it cannot be
measured directly by sampling of blood but
requires either whole-body counting of labeled
MeHg or long-term monitoring of Hg2+ and
MeHg excretion in the absence of prior or sub-
sequent confounding exposures. Consequently,
there are few human data for this parameter.
Miettinen et al. (1971) fed measured portions
of fish containing a known activity of radio-
labeled MeHg to 14 adult subjects, six females
and eight males. Whole-body counting was
used to measure the amount of activity remain-
ing after 3–4 days, and urine and feces counting
was used to measure the excreted activity dur-
ing that period. Miettinen et al. (1971) used
these measurements to estimate the fraction of
the intake dose that was retained/absorbed.
Measurements were taken after the 3–4 day
period presumably to allow elimination of
MeHg that had become associated with the
lining of the gastrointestinal tract but not
absorbed into the body proper. The mean
retention was estimated at 94%. However, dur-
ing this 3–4 day period, some fraction of the
absorbed dose was metabolized to Hg2+ and
excreted. The original Miettinen et al. (1971)
estimate does not account for this metabolism
and thus slightly underestimates the correct
value of this parameter. Previous assessments of
the one-compartment model (Stern 1997;
Swartout and Rice 2000) used this original
Miettinen et al. estimate. However, Miettinen
et al. (1971) also provide individual estimates
of the whole-body half-life of MeHg. This
allows an estimate of the fraction of the
absorbed activity that was eliminated during the
3–4 days due to metabolism. The corrected
value of A is estimated as A = D/(M + U),
where D is the administered MeHg activity, M
is the administered MeHg lost to metabolism,
and U is the administered activity that is
retained at 3–4 days.
The value of A estimated using this
approach (mean ± SD = 0.97 ± 0.016) is 3.4%
larger than the original estimate. The mean
values for males and females are almost identi-
cal, and the entire data set is therefore used
to estimate the distribution of A. Aberg et al.
(1969) also reported that “almost 100%” of
administered MeHg label was absorbed.
Although the available data do not relate to
pregnancy, given the absorption of close to
100% in the nonpregnant state, it does not
seem likely that absorption during pregnancy
would be substantially altered.
The data set is not well ﬁtted by any para-
metric function, and there is some suggestion
of a bimodality, with a secondary peak at
> 99% absorption (Figure 3). The data are
therefore ﬁt to an empirical cumulative prob-
ability distribution. Given the narrow range
of the data, the minimum and maximum val-
ues are selected empirically (0.940 and 0.999,
respectively).
Although the available data are not third-
trimester– or pregnancy-speciﬁc, they are pre-
cise and describe a small range of variability.
Given the likelihood that these values, appar-
ently resulting from simple uptake phenom-
ena, would not change as a result of the
pregnant state, this parameter is judged to
have low true uncertainty.
F—the fraction of the absorbed dose that is
present in the blood at steady state. This para-
meter refers to the fraction of the absorbed
dose of MeHg found in the maternal blood
after distribution among the various tissues.
Functionally, it is derived from the same
data as the elimination rate constant by back
extrapolating the linear ﬁt of the relationship
between time (T) and the log of the Hg con-
centration (or radio-tracer activity) in the
blood to T = 0. This gives the concentration
(or activity) in the blood at the theoretical
point at which MeHg in blood had equili-
brated with other tissues, but before it started
to be eliminated from the blood. This value,
however, must be converted to the mass of
MeHg in the total blood volume and then
expressed as a fraction of the absorbed mass of
MeHg. Thus, F is calculated from 
F = (CT0 × V )/D, 
where CT0 is the concentration of MeHg
in blood at T = 0 (micrograms per liter), V is
the blood volume (liters), and D is the
absorbed dose (micrograms).
Sherlock et al. (1984), Kershaw et al.
(1980), and Smith et al. (1994) do not report
blood volume. Although Kershaw et al. (1980)
and Smith et al. (1994) report values for F, it
appears that blood volumes used in their calcu-
lations were based on an assumed deterministic
relationship between body weight on blood
volume (Allen PV, personal communication).
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Figure 2. Combined third-trimester blood volume
data from Thomson et al. (1938) and Caton et al.
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Figure 3. Comparison of Miettinen et al. (1971) data
on the fraction of MeHg absorbed to maximum likeli-
hood normal and log-normal distributions. In the case of Kershaw et al. (1980), it appears
that blood volume was calculated as 7% of
body mass in kilograms. Individual values of F
for the nonpregnant state can be estimated
from Sherlock et al. (1984) based on their data
for the percentage of intake dose distributed in
1 kg of blood by assuming a deterministic rela-
tionship between body weight and blood vol-
ume. Thus, for consistency with the approach
in Kershaw et al. (1980), blood volume was
estimated for the Sherlock et al. (1984) data
by assuming that blood volume (L) is equal to
7% of body weight (kilograms). However,
estimation of F using such an approach under-
estimates the overall variability in F. For the
Sherlock et al. (1984) data, a further deter-
ministic assumption must be made to estimate
the volume corresponding to 1 kg of blood
(i.e., blood density). This introduces an addi-
tional small loss in variability in the distribu-
tion of F. Standard values for blood density
are generally given as 1.06 kg/L (Reinking
2002; U.S. EPA 2002). Miettinen et al.
(1971), although providing activity versus
time data, provided no data on blood volume
or body weight. These data cannot therefore
be used to estimate F without an arbitrary
assumption of blood volume.
The Sherlock et al. (1984) data show a
moderately negative correlation between the
fraction of the dose in 1 kg of blood and body
weight (r = –0.47, p = 0.04). The authors sug-
gest that this is a function of the larger volume
of distribution to be expected with larger
body masses. Swartout and Rice (2000)
included this correlation in their simulation
of the one-compartment model. This expla-
nation is consistent with the positive correla-
tion between body weight (W) and blood
volume (V) of approximately the same mag-
nitude derived from the data of Thomson
et al. (1938). However, note that the relation-
ship with body weight derived from Sherlock
et al. (1984) refers to the percentage of the
intake found in 1 kg of blood. As body
weight increases, the total blood volume also
increases, and the fraction of the total blood
Hg that is found in a ﬁxed volume (or mass)
of blood (e.g., 1 kg) decreases proportionally.
This will be the case even if the fraction of the
MeHg intake found in the total blood vol-
ume remains constant. Therefore, the correla-
tion observed by Sherlock et al. (1984) does
not appear to reflect a relationship that is
independent of the correlation between body
weigh and blood volume. Thus, having
already speciﬁed that correlation in the model
inputs for W and V, it does not appear neces-
sary to additionally specify a correlation
between W and F.
In both Kershaw et al. (1980) and Smith
et al. (1994), all subjects were men. In the
Sherlock et al. (1984) study, 6 of the 20 sub-
jects were women. The calculated values of F
for the women (mean = 4.59%) were signiﬁ-
cantly less than those for the men (mean =
5.58%; pt-test = 0.014; pMann-Whitney = 0.011).
However, multiple regression analysis of F
shows that when both sex and body weight are
included as independent variables, weight is sig-
niﬁcant (p = 0.03) but sex is not. Thus, sex does
not appear to have an inﬂuence on F indepen-
dent of body weight. The values of F calculated
from Kershaw et al. (1980; mean = 5.63%) and
Sherlock et al. (1984) (mean = 5.28%) are
clearly different from those from Smith et al.
(1994) (mean = 7.7%; pKruskal-Wallis = 0.005).
The Sherlock et al. (1984) and Kershaw et al.
(1980) data, on the other hand, are not statisti-
cally different (pMann-Whitney = 0.35), the small
size of the Kershaw et al. (1980) data set
notwithstanding. Therefore, although the
Sherlock et al. (1984) and Kershaw et al.
(1980) data sets for F appear compatible, the
Smith et al. (1994) data are incompatible.
Differences in body weight between the Smith
et al. subjects and those of Sherlock et al. or
Kershaw et al. do not appear to account for this
difference, and the reason for this difference
is not clear. However, it is possible that the
unknown relationship employed by Smith et al.
(1994) to estimate blood volume from body
weight may contribute to this difference. In
light of the good agreement between the
Sherlock et al. (1984) and Kershaw et al.
(1980) estimates of F, these data sets are
selected as the basis for a distribution for this
parameter.
The combined Sherlock et al. (1984) and
Kershaw et al. (1980) data are consistent with
both normal and log-normal distributions by
standard goodness-of-fit tests. There is little
difference in how well these data are ﬁtted by
these distributions. This may be a function of
the relatively small size of the combined data
set (n = 24). In the absence of further indica-
tions, the normal distribution is chosen to
avoid extreme values in the more elongated
upper tail of the log-normal distribution.
Figure 4 shows the ﬁt of the maximum likeli-
hood normal distribution to these data.
Given the lack of pregnancy-speciﬁc data
for this parameter, the multiple uncertainties
in deriving the parameter from the available
data, the incompatibility of one of the three
available data sets, and the uncertainty in the
specification of the distributional form, this
parameter is assigned a high true uncertainty
estimate.
W—Maternal body weight. Although
cord blood Hg concentration largely reflects
maternal intake during the third trimester, the
changing nature of maternal body weight dur-
ing this period and the lack of a unique refer-
ence point during this period, other than
delivery, make maternal weight at delivery the
most appropriate measure of maternal weight
for this analysis. Directly measured popula-
tion-based data on maternal weight at delivery
for the U.S. population are not available. The
Centers for Disease Control and Prevention
(CDC) does, however, collect individual-
specific data from 19 participating states on
weight gain during pregnancy and prepreg-
nancy weight as part of their Pregnancy Risk
Assessment Monitoring System (PRAMS)
database (CDC 2004b). Data for both para-
meters are partly self-reported. Maternal
weight at delivery is calculated as the sum of
these two quantities. Although the databases
for weight gain and prepregnancy weight are
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Figure 4. Comparison of combined Sherlock et al.
(1984) and Kershaw et al. (1980) data on fraction of
the dose in maternal blood to the maximum likeli-
hood normal distribution.
Table 3. Calculated percentiles of maternal weight
(kg) at delivery (CDC 2004b; Whitehead N, personal
communication).
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Figure 5. Comparison of maternal delivery weight
data (Whitehead N, personal communication) to
the maximum likelihood log-normal distribution.intrinsically linked, corresponding data for indi-
viduals were available only through internal
CDC codes. Linked data were therefore pro-
vided directly in tabulated form (Whitehead N,
personal communication). These data are given
in Table 3.
The CDC (2002) estimated a median
maternal weight gain for all U.S. births of
30.5 lb (13.8 kg). Adding this value to the
estimate of 67.7 kg for the median weight for
all U.S. women 14–44 years of age, derived
from the 2001–2002 National Health and
Nutrition Examination Survey (NHANES)
data (CDC 2004a), gives an estimate of the
median maternal weight at delivery of 81.5 kg.
This agrees reasonably well with the median
value of 77.9 kg from the PRAMS data. A sep-
arate comparison of the prepregnancy weight
component estimated from the PRAMS data to
an estimate of weight for U.S. women of child-
bearing age based on measured values from the
1999–2000 NHANES data (not shown) sug-
gests that the partially self-reported data slightly
overestimate prepregnancy weight for the low-
est percentiles of the distribution and slightly
underestimate prepregnancy weight for the
highest percentiles.
The values given in Table 3 for maternal
weight at delivery as derived from the PRAMS
data are closely ﬁtted by a log-normal distribu-
tion (Figure 5). In the probabilistic analysis,
values of W and V are mutually constrained
based on the correlation coefficient derived
from the data of Thomson et al. (1938).
Although these data are speciﬁc to delivery,
the fact that they result partly from self-reported
information produces some uncertainty. In
addition, they represent data from only 19 of
the 50 U.S. states. There is also a suggestion of
some uncertainty in the tails of the distribution.
Overall, this parameter is associated with a
medium degree of true uncertainty.
Results
Model Outputs
Table 4 summarizes the distribution of the
values estimated for D, the maternal intake
dose corresponding to 58 µg Hg/L cord
blood. Values are the mean of five separate
simulations. The last two rows in Table 4
express the variability in the estimate of the
maternal dose relative to its central tendency
estimate. The ratio of the 50th percentile esti-
mate to the 5th percentile estimate reflects
the “distance” between the median maternal
dose and the maternal dose at which 95% of
the fetal population is predicted to achieve
58 µg/L (i.e., the lower 5% estimate of dose).
Likewise, the ratio of the 50th percentile to
the 1st percentile reﬂects the distance between
the median maternal dose and the maternal
dose at which 99% of the fetal population is
predicted to achieve 58 µg/L (i.e., the lower
1% estimate of dose). Based on this analysis,
the lower 5% estimate of dose is about a factor
of 3 lower than the median dose, and the
lower 1% estimate of dose is a factor of 4
lower than median dose.
Sensitivity Analyses
The derivation of the distributions for each of
the input parameters is associated with varying
degrees of true uncertainty (i.e., lack of knowl-
edge). In the context of this analysis, this
includes both the uncertainty in estimating the
true values of the central tendency and per-
centiles of the input parameters, and to the
uncertainty in specifying their correct distribu-
tional form. In theory, true uncertainty is
reducible through the use of more or better
data. On the other hand, variability is an inher-
ent property of the data and is not reducible
through more or better data.
Sensitivity analysis of variability. Table 5
presents a sensitivity analysis of the contribu-
tions of each of the model input parameters to
the variability in the model output. This is
accomplished in the Monte Carlo simulation
by setting each model parameter, in turn, to its
ﬁxed (point estimate) mean value—that is, by
removing each parameter’s contribution to the
output variability. The resulting model output
is then compared with the model output
reﬂecting the contribution of all of the parame-
ters to the output variability. The magnitude of
the percent difference between these outputs is
a measure of the contribution of each parame-
ter to the total variability. A negative percent
difference indicates that the parameter func-
tions in the full model to increase variability,
and a positive difference indicates that the
parameter functions to decrease variability. In
this analysis, differences in the outputs are
assessed using the ratio of the 50th percentile
value to the 5th or 1st percentile value (i.e., the
normalized lower 95th, and 99th percentiles of
the maternal intake dose resulting in 58 µg/L
Hg in cord blood). This reﬂects the variability
in the portion of the output containing the
sensitive population. Clearly, R makes the
largest contribution to output variability, with
much smaller contributions (in decreasing
order) by b, F, and W. V and A make no signif-
icant contribution to the variability.
Table 5 also presents a summary of the esti-
mates of true uncertainty for each of the input
parameters as discussed in the preceding sec-
tion. Considering the contributions of each
parameter to output variability and true uncer-
tainty together, R, the cord blood:maternal
blood Hg ratio, is the parameter that clearly has
the greatest inﬂuence on variability. However,
it is associated with a low level of true uncer-
tainty and thus makes little contribution to
uncertainty in output variability. The elimina-
tion rate constant, b, makes the next largest
contribution to variability, but its inﬂuence is
only about 20% of R. It is associated with a
moderate level of true uncertainty. Its overall
contribution to uncertainty in the output vari-
ability is therefore relatively small. F, the frac-
tion of the dose residing in the blood, is highly
uncertain but makes only a small contribution
to variability. Its contribution to uncertainty in
output variability is therefore also relatively
small. All other parameters add little or no
uncertainty to the output variability.
Sensitivity analysis of central tendency. If
the central tendency estimates of the input
parameters (i.e., means, medians) in this
analysis are inaccurate, they could bias the
estimates of the central tendency and per-
centiles of the model output even if the vari-
ability in the output distribution is accurately
estimated. Because three of the input parame-
ters are judged to have a low degree of true
uncertainty (Table 5), it is unlikely that they
will contribute signiﬁcantly to uncertainty in
the central tendency estimate of the output.
Therefore, I focused on the variables with
medium or high uncertainty. Because b and
W are judged to have medium uncertainty, I
assumed, for the purposes of this analysis, that
the true mean value could vary from their
original estimate by ± 10%. For F, with high
uncertainty, it was assumed that the true
mean value could vary by ± 20% from its
original estimate. These parameters were
therefore allowed to assume one of three ﬁxed
values: their original estimate of mean value,
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Table 4. Model output of selected percentiles of
the maternal intake dose of MeHg corresponding
to 58 µg Hg/L cord blood.
Distribution of maternal Maternal intake
MeHg intake dose (percentile) dose (µg/kg/day)







Table 5. Estimated contributions of model parameters to variabilityaand true uncertaintybin the model output.
Contribution RbVAF W
50th percentile/5th percentile –37.0 –8.3 < 0.1 +0.4 –5.9 –2.0
50th percentile/1st percentile –49.1 –9.8 +0.3 –1.4 –7.2 –2.1
True uncertainty L M L L H M
See text (“The One-Compartment Model”) for an explanation of the model paremeters.
aPercent change in normalized 5th and 1st percentile values for models with ﬁxed parameters compared to the full variability
model. bEstimates of the degree of true uncertainty in the speciﬁcation of the model parameters: H, high; M, medium; L, low.+10% (or 20% for F) of their original esti-
mate, and –10% (or 20% for F) of their orig-
inal estimate. The remaining parameters were
fixed at the original estimates of their mean
values. The model was calculated using
Monte Carlo sampling (5,000 iterations) to
yield the various possible combinations of
mean maternal dose. Table 6 presents the
results of this analysis.
The minimum and maximum changes
reﬂect the outcomes where the central tenden-
cies of each of the input parameters are simul-
taneously altered in the direction that produces
the greatest change in the output. The values
between the 25th and 75th percentiles reﬂect a
more likely combination of altered input values
resulting in a more likely estimate of the uncer-
tainties in the central tendency estimates.
Under the assumptions of this analysis, the
true uncertainty in the central tendency esti-
mates of the most uncertain input parameters
is most likely to influence the estimate of
maternal dose by ≤ 20%. In addition, because
of the unexplained difference in the value of F
estimated from the Smith et al. (1994) data
compared with the combined Kershaw et al.
(1980) and Sherlock et al. (1984) data, this
analysis was rerun assuming that the maximum
value of F could be 48% larger than the origi-
nal central tendency estimate [i.e., equal to the
mean value from the analysis in Smith et al.
(1994)]. The results of this analysis (not
shown) indicate that, as expected, the use of a
larger value of F results in a smaller value at the
lower end of the range of likely outcomes. The
difference, however (a 28% decrease at the
25th percentile compared with the 20%
decrease seen for the analysis presented in
Table 6), is not dramatic and suggests that, in
the context of the overall uncertainty in the
estimate of central tendency, incorporating the
Smith et al. (1994) value for F would have a
relatively small effect on the central tendency
estimate.
Discussion
This reanalysis of the maternal MeHg dose
resulting in 58 µg Hg/L in fetal cord blood
was undertaken to address two speciﬁc needs
that have arisen since the original NRC and
U.S. EPA analyses. The ﬁrst was to incorpo-
rate the cord blood:maternal blood ratio in
the analysis. This was accomplished by inte-
grating the distribution of R derived in the
recent analysis of Stern and Smith (2003).
The second need was to reduce the uncer-
tainty in the estimate of the central tendency
of the maternal dose. This was accomplished
by reassessing each of the input parameters
in the one-compartment model. This also
allowed a reassessment of the variability in the
estimate of maternal dose. As expected based
on both its central tendency estimate of 1.7
(as opposed to the original implicit estimate
of 1.0) and the signiﬁcant variability around
this value (Stern and Smith 2003), the cord
blood:maternal blood Hg ratio (R) had a sig-
niﬁcant inﬂuence on the estimate of maternal
dose. In addition to proportionally decreasing
the central tendency estimate, this parameter
significantly increased the variability in the
estimate, resulting in a 37% increase in “dis-
tance” between the median and the lower 5th
percentile and a 49% increase in the distance
between the median and the lower 1st per-
centile. The sensitivity analysis of variability
shows that this parameter is the largest source
of variability in the estimate of maternal dose.
Much of the previous uncertainty in the
central tendency estimate of maternal dose
resulted from the lack of temporal speciﬁcity
in the model parameters regarding the period
of pregnancy. In the present analysis, I made
a speciﬁc effort to identify distributional data
that are speciﬁc to pregnancy and, whenever
possible, specific to the third trimester of
pregnancy—the period of gestation corre-
sponding most closely to the period of accu-
mulation of measured Hg in cord blood.
Appropriate pregnancy-specific data were
identiﬁed for four of the six parameters in the
model (excluding C, the empirical value
selected as the point of departure). Third-
trimester–speciﬁc data sets were identiﬁed for
three of these four. As shown in Table 7, the
two largest differences in central tendency val-
ues between the present analysis and the U.S.
EPA analysis are for R and W. The value of
W used in the present analysis is 21% larger
than the value chosen by the U.S. EPA. The
value used in the present analysis is based on
recent data that are speciﬁc to delivery and are
reasonably consistent with independent esti-
mates of pregnancy weight gain and prepreg-
nancy weight. R is entered into the numerator
of the model as its reciprocal, and W appears
in the denominator of the model. Thus, the
effect of increasing the value of both of these
parameters relative to the U.S. EPA estimates
is to decrease the central estimate of the mater-
nal dose. Based on the values in Table 7, the
central tendency estimate of maternal dose
corresponding to 58 µg Hg/L cord blood is
0.7 µg/kg/day. Note that this value differs
from the mean value derived from the full dis-
tributional analysis (Table 4), because the
equation for the model is nonlinear, and
therefore, the mean of the means (i.e., the cen-
tral tendency estimate) is not equivalent to the
overall mean. The corresponding U.S. EPA
central tendency estimate is 1.1 µg/kg/day
(U.S. EPA 2001). When both R and W are set
to their U.S. EPA central tendency values, the
effect of the remaining central tendency val-
ues from the present analysis is to increase
the dose estimate to 1.4 µg/kg/day. Thus,
although individually the changes in b, V, F,
and A are relatively small compared with their
values in the U.S. EPA analysis, the combined
effect of the changes is inﬂuential. Apart from
the extent of change in the central tendency
estimates, the increased specificity and in-
depth evaluation presented here can reduce
the level of uncertainty present in the existing
U.S. EPA analysis.
In addition to the reassessment of the cen-
tral tendency estimates, this analysis yields a
revised analysis of the variability in the esti-
mate of maternal dose. The analysis presented
as part of the NRC report (2000) and dis-
cussed in Stern et al. (2002) concluded that
dividing the central tendency estimate of dose
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Table 6. Sensitivity analysis of the estimates of the central tendency for selected model parameters.
Outcomes from the combination
of alternative central tendency Percent change from
estimates for selected model parameters Estimated mean dose original mean dose
Original mean maternal dose 0.71a —
Minimum alternative value 0.47 –34
Maximum alternative value 1.04 +46
25th percentile alternative value 0.57 –20
75th percentile alternative value 0.84 +18
Values represent the change in the mean maternal dose resulting from various combinations of high and low values for
input parameters. See text (“Sensitivity analysis of central tendency”) for explanation of parameter selection.
aThis value differs from the mean estimated from the full distributional analysis.
Table 7. Comparison of central tendency estimates in the present analysis to central tendency estimates in
the U.S. EPA RfD derivation (U.S. EPA 2001).
Current centrala Pregnancy Third-trimester EPA central Pregnancy Third-trimester
Parameter tendency estimate speciﬁc? speciﬁc? tendency estimate speciﬁc? speciﬁc?
R 1.7 Yes Yes 1.0 (implicit) No No
b 0.0147 day–1 Yes No 0.014 day–1 No No
(47 days) (50 days)
V 5.6 Lb Yes Yes 5 Lc Yes Yes
W 80.9 kg Yes Yes 67 kg Yes No
A 0.97 No No 0.95 No No
F 0.052 No No 0.059 No No
aMeans of ﬁtted distributions (see Table 1). bU.S. women. cNigerian women.Article | Estimation of maternal MeHg intake dose
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by a factor of 2–3 would account for 95–99%
of the variability in the dose estimate. Based
largely on that analysis, the U.S. EPA chose a
value for the 50th percentile:1st percentile
ratio of maternal dose of 3.0 (U.S. EPA 2001).
The central tendency estimate was divided by
this value to obtain an estimate of the 1st per-
centile (i.e., lowest 99th percentile) of maternal
intake dose. In the present analysis, a value of
4.0 is estimated for the 50th percentile:1st per-
centile ratio, and a value of 2.7 for the 50th
percentile:5th percentile ratio (Table 4).
To address the uncertainties in the esti-
mates of the central tendency of the individual
model parameters, the U.S. EPA followed the
recommendation of the NRC to decouple the
central tendency and variability estimates of
maternal dose. By doing so, the U.S. EPA
could explicitly discuss central tendency values
and separately fold the variability into the over-
all consideration of uncertainty factors. For a
cord blood Hg concentration of 58 µg/L, this
approach yields an estimate of the 1st per-
centile of maternal dose of 0.4 µg/kg/day (i.e.,
1.1 µg/kg/day/3.0) based on the U.S. EPA’s
central tendency and variability estimates. To
the extent that the present analysis has substan-
tially reduced the uncertainty in the estimates
of central tendency, it can be argued that this
decoupling is no longer necessary. Rather, I
believe that it is now appropriate to directly esti-
mate the lowest 1st (or any other) percentile of
maternal dose corresponding to 58 µg Hg/L
cord blood directly from the output of the one-
compartment model. With reference to Table 4,
a maternal intake dose of 0.2 µg/kg/day would
correspond to the 1st percentile, and a dose of
0.3 µg/kg/day would correspond to the 5th per-
centile. Thus, the present analysis supports an
estimate that is half of the value implicit in the
U.S. EPA analysis. Following this approach, no
uncertainty factor would be required to
account for pharmacokinetic variability in the
estimate of maternal dose in the calculation of
the RfD. Other uncertainty factors could still
be applied to the derivation of the RfD as
appropriate to address database factors as well
as the remaining fetal variability in the system
including toxicodynamic factors.
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